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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
of unknown etiology affecting diarthrodial joints.
Macrophages are major components in the inflammatory
cascade [1,2] and are also believed to be important media-
tors of joint destruction [3–5]. Large numbers of
macrophages are present in synovial tissue (ST) [6] and
their cell numbers are associated with scores for local
disease activity in clinically involved (CI) joints of RA
patients [7]. Interestingly, increased numbers of
macrophages can also be observed in clinically uninvolved
(CU) joints of RA patients, although their number is lower
than in CI joints [8,9]. The observation that macrophage
numbers are increased in joints that are still clinically quies-
cent could be explained by a difference in functional activity
between macrophages in CU joints and in CI joints [2,10].
Macrophage activity in the synovial compartment includes
the production of chemotactic cytokines called chemo-
kines [11,12]. Chemokines can be generally divided into
four groups: the CXC, C, CX3C and CC chemokine
receptor families [13]. The CXC subfamily includes
CXCL-8 [interleukin (IL)-8], CXCL-9 [monokine induced
by γ-interferon (Mig)], and CXCL10 [interferon-γ inducible
protein-10 (IP-10)]. The best-studied chemokine of this
family is CXCL8, which is produced constitutively by
macrophages in the synovial compartment [14] and is









Paired synovial tissue samples were obtained from both clinically uninvolved (CU) and clinically
involved (CI) knee joints of eight rheumatoid arthritis (RA) patients. In addition, biopsies were taken
from five control subjects. We observed the expression of the chemokines CXCL8, CXCL9, CXCL10,
CCL2 and CCL4 in CI and CU joints of RA patients. In particular, CXCL8 protein levels were
specifically increased in CI joints compared with CU joints, which was confirmed by
immunohistochemistry and in situ hybridization.
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model [15]. CXC chemokines are mostly chemotactic
factors for neutrophils [16], although CXCL10 and CXCL9
attract monocytes and T lymphocytes [17]. The CC
chemokines include CCL2 [monocyte chemoattractant
protein 1] [18] and CCL4 [macrophage-inhibiting protein-1β
(MIP-1β)] [19]. The main function of both CCL2 and CCL4
seems to be the recruitment of macrophages [19–21].
To investigate the role of chemokines in relation to clinical
signs of synovitis, we determined chemokine expression in
paired CU and CI RA knee joints.
Materials and methods
Patients
Eight patients with RA (ACR 1987 criteria [22]) and both
a CI and a CU knee joint were investigated. The knee was
considered uninvolved if the patient noticed no pain or lim-
itation of range of motion and two independent observers
could not detect signs of inflammation such as swelling,
warmth, effusion, or pain on examination. The knee was
considered involved if there were signs of inflammation,
namely joint effusion, synovial swelling, and pain. Five sub-
jects without inflammatory joint disease and meniscus
pathology served as control subjects. All patients gave
informed consent, and the Medical Ethics Committee of
the Leiden University Medical Center approved the study
protocol. The mean ages were similar for patients and
controls. The mean disease duration of the RA patients
was 73 months (range 3–252 months). Most RA patients
had active disease in other joints in addition to the knee
joint from which the synovial biopsies were obtained. The
mean Ritchie articular index [23] was 11 (range 3–24)
and the mean serum level of C-reactive protein (CRP) was
69 mg/l (range 4–108 mg/l). In six of the eight RA patients
the CU joint had shown clinical signs of arthritis at previ-
ous phases of the disease.
Arthroscopy
In all RA patients an arthroscopy procedure was per-
formed in both knees with a small-bore 2.4 mm arthro-
scope (Storz, Tuttlingen, Germany) by a single skin portal
in the suprapatellar pouch both for macroscopic examina-
tion of the synovium and for the biopsy procedure. At each
arthroscopy, synovial biopsies were taken from the supra-
patellar pouch, the synovium–cartilage junction, the patel-
lar gutters, and the tibia–femur junction with a 2.0 mm
grasping forceps (Storz). If there was macroscopic varia-
tion of synovitis, samples were taken from both macro-
scopically inflamed and macroscopically non-inflamed
regions. The ST from all five control patients with menis-
cus pathology was obtained by arthroscopy with a 5.0 mm
grasping forceps before the meniscectomy. On average,
20 ST samples from one knee joint were snap-frozen in
methylbutane (–80°C) and used for tissue enzyme-linked
immunosorbent assay (ELISA). Biopsy samples were
stored in liquid nitrogen. On average, five ST samples from
one knee joint were fixed in formalin and subsequently
embedded in paraffin and then used for immunohisto-
chemistry and in situ hybridization.
Tissue ELISA
ST protein extracts were prepared by mincing tissues in 2
volumes of extraction buffer [1% Tween 20, 1 M NaCl,
0.1% NaN3 in phosphate-buffered saline (PBS)], incubat-
ing the mixture on ice for 1 h and sonicating for 5 min in a
water bath sonicator. After centrifugation at 10,000g for
10 min, the supernatant was collected, diluted with 9
volumes of PBS and stored at –80°C or immediately
assayed for protein concentration by the bicinchoninic
acid assay (Pierce). Chemokine protein levels were quanti-
fied by sandwich ELISA with matched antibody pairs.
ELISA plates (Costar) were coated with 100–400 ng per
well of capture antibody [6217.11 for CXCL8 (R&D
Systems, Minneapolis, Minnesota, USA); B8-11 for
CXCL9 (PharMingen); 4D5/A7/C5 for CXCL10 (PharMin-
gen); polyclonal rabbit antibodies against monocyte
chemoattractant protein, for CCL2 (Endogen, Woburn,
Massachusetts, USA); and 24006.111 for CCL4 (R&D
Systems)] in PBS overnight at 4°C, blocked with block
buffer [PBS containing 1% (w/v) BSA, 5% (w/v) sucrose
and 0.05% NaN3] for 2 h at room temperature, and
washed with wash buffer (0.05% Tween 20 in PBS).
Samples (100 µl) and standards were incubated for 2 h at
room temperature, washed, and incubated with 2 ng per
well of polyclonal biotinylated antibodies against CXCL8
(R&D Systems) or CCL4 (R&D) or 20–400 ng per well of
monoclonal antibodies 6D4/D6/G2 against CXCL10
(PharMingen), T-MCAF2 against CCL2 (Endogen) or
B8-6 against CXCL-9 (PharMingen) for 2 h at room tem-
perature. After washing, 0.1 ng/ml horseradish peroxidase-
conjugated streptavidin (Zymed, South San Francisco,
California, USA) was added for 20 min at room tempera-
ture, washed and developed with tetramethyl benzidine
(TMB) peroxidase substrate (Kirkegaard and Perry Labora-
tories, Gaithersburg, Maryland, USA) for 20 min. The per-
oxidase reaction was stopped by the addition of 0.5
volume of 1 M phosphoric acid and the plate was read at
450 nm in an ELISA plate reader (Anthos, Durham, North
Carolina, USA).
Immunohistochemistry
Formalin-fixed, paraffin-embedded ST was cut into 5 µm
sections and placed on slides coated with 2% 3-amino-
propyltriethoxysilane (Sigma, St Louis, Missouri, USA).
Immunohistochemical staining was performed with a
monoclonal mouse antibody against CXCL8 (R&D
Systems), as described previously [24,25]. In brief, we
used alkaline phosphatase-conjugated antibodies (Dako,
Glostrup, Denmark), napthol-AS-MX-phosphate, Fast Red
Violet LB and levamisole (Sigma) for detection of the mon-
oclonal antibody. All ST samples were processed in the
same run. Negative control experiments were performed
with irrelevant isotype control antibodies (X63 and
FMC41) or normal donkey serum alone, or by leaving out
the secondary antibody. A positive control (ST with known
staining characteristics) was also used in each run.
Hybridization in situ
The cDNA used to produce CXCL8 riboprobes was
obtained from Dr Phil Auron (Boston, Massachusetts,
USA) and was restricted to 800 base pairs within the
coding sequence. The generation of riboprobes was per-
formed as described previously [26]. The RNA copies
were run off with a commercial riboprobe generation kit,
which included digoxigenin-labeled dideoxyuridine triphos-
phate (Boehringer-Mannheim, Mannheim, Germany) as
part of the nucleotide mix. Subsequently, paraffin-
embedded tissue sections were processed as described
previously [26]. In brief, after washing steps with 0.2M HCl
and diethyl pyrocarbonate-treated water the sections were
digested in proteinase K. After washing steps with SSC
(0.3M NaCl and 0.03M sodium citrate, pH 7.0), sections
were incubated with prehybridization solution. The prehy-
bridization solution was replaced by a previously tested
amount of labeled RNA anti-sense probe (or labeled RNA
sense probe as a control). Sections were covered with
coverslips, sealed with nail polish, and incubated overnight
at 55°C. For visualization of the probes, sections were
incubated with digoxigenin labeling solution and labeled
with nitro blue tetrazolium and 5-bromo-4-chloroindol-3-yl
phosphate. All sections were counterstained with hema-
toxylin. Slides were mounted in Aquamount (BDH Labora-
tories, Poole, UK) with a coverslip.
Digital image analysis
One observer (MCK) performed the processing of all
images. Five randomly selected high-power fields were
chosen for the evaluation of each section, as described
previously [27,28]. Each high-power field contained both
intimal lining layer and synovial sublining. The high-power
field images were acquired on a Olympus microscope
(Olympus, Japan, Tokyo), and were captured with a CCD
(charge-coupled device) three-chip video camera (Sony,
Tokyo, Japan), and were digitized with a PV100 multime-
dia 16-bit color video digitizer card with a standardized
macro program to both simplify and standardize the acqui-
sition process. The resultant color images were in a
640 × 480 pixel RGB (red, green, and blue) format with a
24-bit resolution, enabling the use of 16,581,375 colors.
For each acquisition session the microscope, camera, and
computer were calibrated with a standardized procedure.
The images obtained were stored as bitmaps without
compression with a Zip disk and portable driver (Iomega,
Roy, Utah, USA).
All sections were examined with a Qwin (Qwin Pro V2.2;
Leica, Cambridge, UK) computer-assisted color video
image analysis systems. This system consisted of a PC
with software. Two binary masks were applied with thresh-
old values for the red, green, and blue channels. These
thresholds were kept constant for all measurements with
the same marker. A first binary mask identified the counter-
stained areas as reference for the total region of tissue,
and a second binary mask covered the positively stained
areas. Both binary masks were processed individually to
decrease the signal:noise ratio with erode, open, and
dilate commands. Overlapping areas between the two
binary masks were identified and they were not included in
the analysis. Analysis was performed on the absolute area
stained as indicated by the secondary binary mask. For the
assessment of CXCL8 staining, the area was measured in
pixels, the mean optical density was measured and the
integrated optical density (IOD) was calculated by multipli-
cation of the relative or absolute stained area by the mean
optical density.
Statistical analysis
Data were analyzed with the following nonparametric
tests: Wilcoxon signed ranks test for matched pairs com-
paring CI knee joints with CU knee joints, and Mann–




Differences in chemokine expression between control, CI,
and CU joints were screened by determining protein
expression in synovial extracts. The CXC chemokines
CXCL8, CXCL9, and CXCL10, and the CC chemokines
CCL2 and CCL4 could be detected in rheumatoid ST. In
three of the eight patients, CXCL8 expression was
detected in the CU joint (0.1±0.06ng of chemokine/mg of
tissue extract; mean±SEM) and it was increased in the CI
joint (0.3±0.13ng/mg), but CXCL8 was not detectable in
the two control patients that were tested (Fig. 1). CCL2
expression was detected in five of six CU joints
(0.9±0.5ng/mg), two of four patients showed increased
expression in the CI joint (1.0±0.2ng/mg), and one of two
controls had detectable levels (0.1±0.0ng/mg) (Fig. 1).
CXCL9 expression was detected in four of the six CU
joints (9.1 ± 8.3 ng/mg), two of four patients showed
increased expression in CI joints (8.0 ± 2.7 ng/mg), and
CXCL9 was not detectable in two controls (Fig. 1).
CXCL10 expression was detected in two of the six CU
joints (0.2 ± 0.2 ng/mg), whereas two of four patients
showed increased expression in CI joints
(0.4 ± 0.2 ng/mg), and CXCL10 was not detectable in two
controls (Fig. 1). CCL4 expression was detected in three
of six CU joints (0.1 ± 0.1 ng/mg); one of four patients
showed increased expression in the CI joint
(0.2 ± 0.1 ng/mg), and CCL4 was not detectable in two
controls (Fig. 1). Differences between CI knees, CU knees
and control patients were not statistically significant, pos-










To confirm and extend the observation that CXCL8
expression was higher in CI joints than in CU joints,
immunohistologic analysis was performed. In one of the
patients, the ST from the CI joint was not assessable.
Expression of CXCL8 was observed in both the intimal
lining layer and the synovial sublining (Fig. 2). There was
markedly increased CXCL8 protein expression in six of the
seven CI joints (IOD 65,961 ± 5364) compared with CU
joints (IOD 28,552 ± 5749) (P < 0.05), whereas the eight
CU joints showed similar results compared with the five
control subjects (IOD 34,599 ± 5144) (Figs 3 and 4).
In situ hybridization
The increased expression of CXCL8 in CI joints compared
with CU joints was confirmed by in situ hybridization to quan-
tify CXCL8 mRNA expression. In one of the patients the ST
from the CI joint was not assessable. CXCL8mRNA expres-
sion in all seven CI joints (IOD 17,109±6944) was specifi-
cally increased compared with the eight CU joints (IOD
2774±1415) (P<0.05) and the five control subjects (IOD
180±66) (Figs 3 and 4). The values for CU and normal con-
trols were essentially the same, as shown in Fig. 3.
Discussion
The results presented here show protein expression of the
CXC chemokines CXCL8, CXCL9, and CXCL10, and the
CC chemokines CCL2 and CCL4 in rheumatoid ST by
tissue ELISA. CXCL8 protein levels were increased in CI
joints compared with CU joints. Immunohistochemistry
and in situ hybridization confirmed the results for CXCL8.
Macrophages are major components of the inflammatory
cascade involved in synovitis [1], and increasing evidence
indicates that there is a distinct role for macrophage-derived
cytokines in this process. Tumor necrosis factor-α (TNF-α)
and IL-1β are important mediators of synovial inflammation
and joint destruction [29–31]. In addition, the release of
chemokines from inflammatory cells has a pivotal role in the
development of inflammation [13,32,33]. The coordinated
production of chemokines and proinflammatory cytokines is
also important for the orchestration of the inflammatory
response observed in patients with active RA [12,34]. In
RA, chemokines are involved in the infiltration of the syn-
ovium by leukocytes [12,35,36]. Chemokines such as
CXCL8, CCL2, and CCL4 [12,37] are readily detectable in
rheumatoid synovial fluid, and their expression is correlated
with disease activity [38,39]. CXCL8 expression in rheuma-
toid ST is also associated with disease activity [39,40]. In
addition, the chemokines CCL2 [18,35,41] and CCL4 [42]
have been detected in ST in RA. CXCL9 and CXCL10 are
also abundantly expressed in RA synovium [43]. The
increased presence of the C–C chemokines CCL2 and
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Figure 1
Chemokine levels in tissue extracts from clinically uninvolved (CU)
compared to clinically involved (CI) joints in paired (connected, filled
circles) synovial biopsies from eight patients with RA. Also shown are
results from unpaired (open circles) synovial biopsies. Chemokine
levels are expressed as ng/mg of tissue extract.
Figure 2
Representative examples of synovial tissue sections stained for
interleukin-8 (CXCL8) protein expression [immunohistochemistry,
CXCL8 monoclonal antibody (mAb)] and CXCL8 mRNA expression
(in-situ hybridization, anti-sense CXCL8 riboprobe) in normal synovium
and in synovial tissue from paired clinically uninvolved knee joints and
clinically involved knee joints of rheumatoid arthritis (RA) patients and
control sections with a sense probe or aspecific mAb. 
CCL4 in both CU and CI knee joints compared with con-
trols is consistent with the increased macrophage numbers
present in both CU and CI knee joints [8]. Both CCL2 and
CCL4 are chemoattractants that act mainly on monocytes/
macrophages and also regulate their expression of adhe-
sion molecules [44–46]. We have previously shown that
increased macrophage numbers can be found in CI as well
as CU joints of RA patients [8].
The CXC chemokines CXCL10 and CXCL9 were unde-
tectable in control patients and expressed equally in CU
and CI knee joints. Both are associated mainly with the
attraction of activated T cells [17], which are thought to
have a role in the pathogenesis of RA [47,48]. In line with
our previous studies, the results presented here show no
direct relationship between the number of T cells in the
synovium and clinical signs of arthritis [7,8].
The observed difference in CXCL8 expression between
CU and CI knee joints described here is a close reflection
of the observations in animal models of crystal-induced
arthritis where CXCL8 was the single factor determining
the development of clinical signs and symptoms of arthritis
[15,41,49]. Furthermore, neutralization of CXCL8-attenu-
ated crystal-induced arthritis in an animal model [49] and
RA patients treated with a high dose of methylprednisolone
displayed a significant decrease in CXCL8 expression in
ST biopsies together with an excellent clinical response
[50]. This phenomenon could be explained by the attrac-
tion of neutrophils towards the synovial compartment under
the influence of CXCL8 [15,19,51–54]. Once neutrophils
have arrived at the site of inflammation they are activated
and contain a variety of proteinases and other enzymes,
such as collagenase, elastase, gelatinase, myeloperoxi-
dase, prostaglandins, and leukotrienes [55]. They also
release proteins such as fibronectin, and cytokines includ-
ing IL-1β [56], TNF-α [57], and CXCL8 [58]. Thus, the
increased ingress of neutrophils into the synovial compart-
ment and their prolonged lifespan [59] in response to
CXCL8 might be important in the development of clinical
symptoms, including swelling and pain. Therefore, targeting
CXCL8 could be an effective anti-rheumatic treatment. This
notion is supported by the observation that CXCL8mRNA
expression is decreased after treatment of antigen-induced
arthritis [41]. Specific inhibition of CXCL8 by therapy with
monoclonal antibody has been shown to be effective in an
acute model of arthritis [60]. In RA patients, decreased
CXCL8 production has been observed after treatment with
methotrexate [61]. Furthermore, treatment with corticos-
teroids results in decreased expression of CXCL8 in ST
and CXCL8 levels in synovial fluid, decreased migration of
neutrophils into the joint, and diminished arthritis activity
[29,30,51]. Studies on the effects of specific targeting of
CXCL8 in RA patients are not yet available.
In conclusion, this study demonstrates the expression of
CCL2, CXCL10, CCL4, CXCL9, and CXCL8 in ST of RA
patients. Increased synthesis and expression of CXCL8 is
associated with clinical signs and symptoms of arthritis.
Future research should be directed toward elucidating
which factors determine the specific upregulation of
CXCL8 synthesis by macrophages in clinically inflamed










Mean integrated optical density (IOD) for interleukin-8 (CXCL8)
protein expression (immunohistochemistry) and CXCL8 mRNA
expression (in situ hybridization) in normal synovium and in synovial
tissue from paired clinically uninvolved knee joints and clinically
involved knee joints of rheumatoid arthritis (RA) patients. Abbreviation:
ns, not significant.
Figure 4
Interleukin-8 (CXCL8) expression and mRNA levels in synovial tissue
(ST) from clinically uninvolved (CU) and from clinically involved (CI)
joints in paired synovial biopsies from seven patients with rheumatoid
arthritis (RA) (connected, filled circles). Also shown are results from
one unpaired (open circles) synovial biopsy. CXCL8 levels are
expressed as integrated optical density measured with digital image
analysis on ST sections stained immunohistochemically and with in
situ hybridization.
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